Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

Cyclophosphamide 641 Bevacizumab 552 Paclitaxel 534 Carboplatin 533 Cisplatin 480 pembrolizumab 456 Gemcitabine 422 Docetaxel 415 Rituximab 386 Radiotherapy 373 Dexamethasone 351 Doxorubicin 330 Nivolumab 308 Fluorouracil 286 Capecitabine 260 Etoposide 245 Prednisone 244 Oxaliplatin 242 Erlotinib Hydrochloride 242 Cytarabine 233 Lenalidomide 232 Trastuzumab 226 Pemetrexed 220 Vincristine 212 fludarabine phosphate 208 Leucovorin 208 Cetuximab 208 Filgrastim 204 Bortezomib 193 Methotrexate 183

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Has results × empagliflozin × Clear all

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡